분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-07 14:06:16 , Hit : 1528
 J&J Wins U.S. Approval for Hepatitis C Combo With Gilead



Bloomberg News

By Anna Edney   November 06, 2014

--------------------------------------------------------------------------------

      Johnson & Johnson (JNJ:US) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD:US)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus.

The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like side effects.

The price of hepatitis C treatments has been criticized by insurers and lawmakers since Foster City, California-based Gilead’s Sovaldi was approved in December with an $84,000 price tag for a full course of treatment. The FDA on Oct. 10 cleared Gilead’s Harvoni, a once-daily pill that treats patients who have the most common form of the virus without using the older drugs. Harvoni has an estimated cost of $94,500 for 12 weeks.

Video: Stockton, CA, Wins Court Approval of Bankruptcy Plan

J&J hasn’t changed the $66,000 price for 12 weeks of therapy with Olysio since it was first cleared for use with older medicines in the U.S. a year ago, said Rebecca Tillet, a company spokeswoman. J&J plans to work with insurance companies and other payers to ensure it continues to provide access to patients, she said in a telephone interview.

“There are a lot of different patients needs,” she said. “We think Olysio will play a meaningful role in that mix.”

Patient Population

About 3.2 million people in the U.S. have hepatitis C, which can cause liver cirrhosis according to the Centers for Disease Control and Prevention. The most common form of the virus is genotype 1, which affects about 75 percent of patients. J&J, based in New Brunswick, New Jersey, and Swedish drugmaker Medivir AB (MVIRB) sell Olysio. The drug, in combination with ribavirin and interferon, can treat patients in 24 weeks, half the time of older medicines.

Video: Apple Wins in Court, Won’t Pay $93.7M Fine

J&J, the world’s largest health-care products company, reported Olysio revenue (JNJ:US) of almost $2 billion in the first three quarters of this year. Sovaldi has generated $8.6 billion in sales during the same time period.

Patients have been able use J&J’s Olysio and Gilead’s Sovaldi together without FDA clearance at a cost of $150,000. Doctors may prescribe drugs approved for specific diseases to treat other ailments in a practice called off-label use.

The drugs are part of a push to shorten treatment times while improving cure rates and eliminating unpleasant side effects. Older drugs include Merck & Co.’s Victrelis and Vertex Pharmaceuticals Inc. (VRTX:US)’s Incivek.

Video: Nurse Wins Freedom From New Jersey Ebola Quarantine

The FDA approved the combination treatment for a standard 12 weeks of therapy if patients don’t have cirrhosis and 24 weeks for those who do, according to the drug’s prescribing label.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editors responsible for this story: Crayton Harrison at tharrison5@bloomberg.net Andrew Pollack, James Callan







967   핵심 암 유전자의 마스터 조절자 발견  이성욱 2014/07/01 1499
966   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1500
965   AbbVie says hepatitis C regimen gets nod for FDA priority review  이성욱 2014/06/17 1503
964   화학적 태그로 미래의 마이크로 RNA 표시  이성욱 2015/03/30 1505
963   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1508
962   Sovaldi forces Incivek off the hep C market as Vertex calls it quits  이성욱 2014/08/15 1516
961   Stem cell treatment causes nasal growth in woman's back  이성욱 2014/07/09 1517
  J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1528
959   텔로미어 연장을 통해 인간 세포의 노화시계를 되돌리는 데 성공  이성욱 2015/02/04 1534
958   서아프리카의 에볼라 사태, 전 지구적 재앙으로 이어질 수 있을까?  이성욱 2014/08/06 1542
957   인간 노화 조절 가능하다  이성욱 2015/05/04 1544
956   신약 개발을 위한 Cas9 동물 모델의 개발  이성욱 2014/10/02 1548
955   남성 생식력에 부정적인 영향을 주는 핸드폰  이성욱 2014/06/14 1563
954   자가 항체에 의한 전신 홍반성 루프스 발생 기작  이성욱 2015/01/05 1570
953   대장암 종양 성장과 밀접한 마이크로 알앤에이  이성욱 2014/10/06 1572
952   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1577
951   세계의 과학자들, 성인의 세포를 이용해 배아줄기세포를 만드는 데 잇달아 성공  이성욱 2014/04/30 1586
950   암에서 마이크로RNA를 조절하는 새로운 초-보존 RNA 규명!  이성욱 2014/06/12 1592
949   Three studies show that the virus can cause birth defects in mouse embryos.  이성욱 2016/05/13 1593
948   DNA의 규칙을 배반한 미생물  이성욱 2014/05/27 1600

[이전 10개] [1]..[11][12][13][14][15] 16 [17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN